Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Colorectal Cancer.
The Global Colorectal Cancer Market size & share was valued at approximately USD 21.9 billion in 2023, reached USD 22.3 billion in 2024 and is expected to reach a value of around USD 30.1 billion by 2033, at a compound annual growth rate (CAGR) of about 3.4% during the forecast period 2024 to 2033.
Colorectal cancer is one of the most prevalent cancers worldwide, with its incidence increasing globally. According to a study published in the National Library of Medicine in October 2021, colorectal cancer (CRC) accounted for approximately 10.0% of the global cancer incidence in 2020, and 9.4% of the deaths, making it the second deadliest cancer type, following lung cancer, which accounted for 18% cancer deaths worldwide.
The development and adoption of advanced screening methods such as colonoscopies, fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and genetic testing have improved early detection rates.
North America accounted for the largest revenue share of 42.6% in 2022. Asia-Pacific is expected to grow at the highest CAGR of 6.7% during the forecast period due to the rising geriatric population and increasing participation of public and private establishments to organize awareness programs on colorectal cancer. The key players in the market are focusing on product approvals & launches, strategic partnerships, mergers & acquisitions, and global expansions to strengthen their industry position.
For additional information on Colorectal Cancer, please review the video by Medical Centric.